Eyenovia, Inc. showcased the Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas, Nevada, from Jan. 5-8. Eyenovia highlighted the technology and its human-centric approach to ocular drug delivery to over 115,000 attendees. The microdosing technology behind Optejet® prioritizes ease of use, appropriate dosing, and reducing wasted medication by administering one-fifth the volume of a solution compared to a traditional eyedropper.

This method of drug delivery may reduce the risk of overdosing, which may lead to less adverse side effects and offers patients an easier, more precise way to dispense eye drop medications. Eyenovia presented its latest human-centric innovations in the Digital Health and Startups category to an audience of over 4,700 media professionals and outlets. The 2023 Consumer Electronics Show brings together more than 3,200 exhibitors representing 173 countries, territories, and regions.

Eyenovia is creating an entire pipeline of advanced therapeutics based on its proprietary Microdose Array Print (MAP™) platform technology. The Optejet® dispenser is the technology underlying Eyenovia's research and development targeting progressive myopia, presbyopia and mydriasis. Optejet® has not been approved, cleared, or licensed by the U.S. Food and Drug Administration for any use, and it is not commercially available in the United States.